1. Sweden Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
BioGaia AB Class B

BioGaia AB Class B

11.55
USD
-0.65
(-5.33%)
0.38EPS
32.57P/E
1.24BMarket Cap
Feb 12Next Earn
BioGaia AB Class B
OTC:BGLAF
(OTC Markets)

Recent

price

11.55

P/E

ratio

32.57

div

yld

9.73%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
SEK
2.74
3.65
7.47
3.65
5.58
5.58
6.17
7.1
8.56
8.79
8.37
7.77
10.93
12.84
14.08
15.2
16.4
Revenue per Share
0.55
0.88
3.79
0.71
1.71
1.4
2.63
2.08
2.48
2.14
2.01
1.94
3.7
3.62
3.48
3.29
3.65
Basic EPS, GAAP
0.79
0.66
3.55
0.71
1.16
1.03
1.64
2.26
1.96
1.25
2.3
2.13
2.98
3.74
3.55
2.99
2.63
Free Cash Flow per Basic Share
0.3
0.4
1.2
2
1.4
1
1.43
1.5
1.8
1.98
0.73
0.68
2.98
2.9
6.89
6.9
10.9
Dividend per Share
2.17
2.66
5.25
3.67
3.99
4.57
4.79
5.35
5.83
5.86
17.29
18.59
19.53
20.11
17.04
12.99
10.88
Book Value per Share
2.15
2.66
5.25
3.67
3.92
4.38
4.79
5.35
5.24
5.19
16.74
16.64
17.38
18.01
15.3
11.54
9.35
Tangible Book Value per Share
86
86
86
86
86
87
87
87
87
87
89
101
101
101
101
101
101
Basic Weighted Avg Shares
236
315
645
316
482
483
535
615
742
768
747
785
1,104
1,297
1,423
1,538
1,659
Sales/Revenue/Turnover
24.71
32.65
66.34
25.28
39.26
35.4
36.47
38.78
37.12
32.54
32.73
30.89
30.3
34.01
28.77
29.38
27.89
Operating Margin (%)
3
5
5
6
6
7
7
7
8
16
21
27
24
25
26
25
24
Depreciation Expense
47
76
327
62
147
121
228
181
215
187
180
196
374
365
351
333
369
Net Income, GAAP
32.31
26.95
25.41
23.37
23.13
22.81
18.72
22.48
22.83
22.7
21.03
22.33
16.5
22.07
21.53
21
21.36
Effective Tax Rate (%)
20.02
24.24
50.67
19.54
30.59
25.12
42.56
29.36
28.97
24.38
24.06
25
33.86
28.18
24.7
21.63
22.26
Profit Margin (%)
167
206
432
257
262
288
312
343
349
328
1,555
1,625
1,632
1,679
1,404
1,020
729
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
187
230
457
317
345
396
415
464
508
508
1,746
1,877
1,972
2,030
1,724
1,314
1,101
Total Equity
20.68
33.5
91.08
15.54
43.29
35.61
39.81
40.64
42.9
35.74
15.78
10.78
15.55
17.08
17.48
21.42
25.26
Return on Invested Capital (%)
27.08
34.97
94.32
15.32
44.39
32.83
56.19
41.13
44.42
36.68
15.86
10.82
19.6
18.29
18.78
22.22
25.9
Return on Capital (%)
27.12
36.63
95.74
16.02
44.54
32.8
56.12
41.08
44.36
36.99
15.95
10.83
19.42
18.26
18.72
21.91
25.64
Return on Common Equity (%)

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
101
101
101
Market Capitalization
10,150
10,994
12,025

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,219
1,316
941
Cash, Cash Equivalents & STI
801
872
446
Accounts Receivable, Net
216
- -
- -
Inventories
167
- -
- -
Total Current Liabilities
199
266
212
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
24.66%
-4.67%
-23.77%
Free Cash Flow
18.54%
9.92%
-15.62%
Net Income, GAAP
15.72%
17.65%
-5.3%
Sales/Revenue/Turnover
12.81%
16.2%
8.11%
Total Cash Common Dividend
49.59%
95.75%
0.18%

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
370
384
304
365
1,423
2025
366
405
- -
441
1,538
2026
373
441
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.21
1.1
0.36
0.81
3.48
2025
0.79
0.87
- -
0.98
3.29
2026
0.78
1.02
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
6.9
- -
- -
6.89
2025
- -
6.9
- -
- -
6.9
2026
- -
4
- -
- -
- -
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
BioGaia AB (publ) develops, manufactures, markets and sells probiotic products based on patented Lactobacillus reuteri strains for gut health, immune health and oral health; offers drops, chewable tablets, oral rehydration solutions, gut health tablets, bone health tablets and oral health lozenges under the BioGaia brand including Protectis (L. reuteri DSM 17938), Prodentis (DSM 17938 and ATCC PTA 5289) and Gastrus (DSM 17938 and ATCC PTA 6475); provides cultures as ingredients for infant formula, milk formula and licensee dairy products; and supplies packaging solutions through its Other segment. The company operates in Pediatrics, Adult Health and Other segments, targeting infantile colic, digestive health in children, antibiotic-associated and acute diarrhea, gingivitis, periodontal disease, general health, H. pylori infection, low bone density and irritable bowel syndrome symptoms; sells through distribution partners and own channels in over 100 countries across EMEA (Europe, Middle East, Africa), Americas (USA, Canada, South America), APAC (Asia-Pacific), Australia and New Zealand. Founded in 1990 and headquartered in Stockholm, Sweden, BioGaia conducts research with over 270 published studies and holds 600 patents on its strains. In 2024, Anatom Holding AG acquired nearly 5 million class B shares following EQT Public Value fund's exit; the company launched BioGaia Gastrus PURE ACTION, a FODMAP-friendly, double-strength probiotic capsule for sensitive stomachs; terminated its France distribution contract to shift to direct operations; and in July 2025 established subsidiary BioGaia New Sciences AB to advance microbiome research into skin health and biotics beyond core areas. In Q3 2025, net sales rose 7% to SEK 326.6 million with Pediatrics up 7% and continued APAC and Americas growth via online sales and direct markets in Australia and New Zealand.

Company News

Company News APIChatGPT

  • seekingalpha.com

    BioGaia AB (publ) (BIOGY) Q2 2026 Earnings Call Transcript

  • seekingalpha.com

    BioGaia AB (publ) (BIOGY) Q3 2025 Earnings Call Transcript